Yahoo Finance

IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program

POTOMAC, MARYLAND / ACCESS Newswire / April 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the expansion of its ongoing Phase 2 CALMA clinical trial ...

IGC Pharma, Inc.: IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities - POTOMAC, MD / ACCESS Newswire / January 12, 2026 / IGC Pharma, Inc. (NYS ...
Yahoo Finance

IGC Pharma expands CALMA trial with addition of Butler Hospital Program

IGC Pharma (IGC) announced the expansion of its ongoing Phase 2 CALMA clinical trial with the addition of Butler Hospital’s Memory and Aging Program, a research center affiliated with the Warren ...
WJHL-TV

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc.
Seeking Alpha

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Canadian Hamilton Health Sciences

POTOMAC, MD / ACCESS Newswire / March 20, 2025 / IGC Pharma, Inc. ("IGC", or the "Company") (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 CALMA trial for IGC-AD1 with the ...
Seeking Alpha

IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

POTOMAC, MD / ACCESS Newswire / September 22, 2025 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage pharmaceutical company focused on therapies for Alzheimer's disease, today announced it has ...
PharmiWeb

IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health

POTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of ...
Eagle-Tribune

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

POTOMAC, MARYLAND / ACCESS Newswire / December 9, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) ...
PharmiWeb

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

POTOMAC, MARYLAND / ACCESS Newswire / November 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company leveraging Artificial Intelligence (AI) ...
Nasdaq

IGC Pharma Achieves 65% Enrollment In Phase 2 CALMA Trial For Alzheimer's Agitation

(RTTNews) - IGC Pharma, Inc. (IGC), a clinical-stage biotechnology company, has announced that it has reached 65% patient enrolment in its ongoing Phase 2 CALMA trial evaluating IGC-AD1 for the ...